A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
NCT06010524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2023-08-29
Summary
This is a retrospective, non-interventional study. Investigators from infectious diseases and gastroenterology departments will participate this study.
Patients data will be collected from hospital medical records.
Conditions
- Hepatitis C
Sponsors & Collaborators
-
Cerrahpasa Medical Faculty Foundation
lead OTHER
Principal Investigators
-
Fehmi Tabak, Prof · Cerrahpasa Medical Faculty
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-01
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
NCT02639247 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
NCT02671500 ·Status: COMPLETED ·Phase: PHASE3
-
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
NCT03074331 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
NCT02607735 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
NCT02745535 ·Status: COMPLETED ·Phase: PHASE2
-
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
NCT02346721 ·Status: COMPLETED ·Phase: PHASE3
-
Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
NCT03118843 ·Status: COMPLETED ·Phase: PHASE3
-
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
NCT02781571 ·Status: COMPLETED ·Phase: PHASE2
-
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
NCT02728206 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
NCT02607800 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
NCT02378961 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
NCT02201953 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
NCT04695769 ·Status: COMPLETED ·Phase: PHASE4
-
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
NCT02201901 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
NCT02536313 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
NCT02378935 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
NCT03820258 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
NCT02639338 ·Status: COMPLETED ·Phase: PHASE3
-
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
NCT05092074 ·Status: UNKNOWN
-
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
NCT02994056 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
NCT02722837 ·Status: COMPLETED ·Phase: PHASE3
-
Direct Acting Agents in Hepatitis C Patients
NCT03145844 ·Status: COMPLETED
-
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
NCT04997564 ·Status: UNKNOWN ·Phase: PHASE4
-
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
NCT02822794 ·Status: COMPLETED ·Phase: PHASE3
-
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
NCT02292706 ·Status: TERMINATED